REGISTER NOW: Webinar: Orphan Drugs - A flattening curve?
Thursday 16th March 3pm GMT | 11am EST
Drug developers have maintained a strong focus on orphan indications, with orphan drugs becoming one of the fastest growing areas of drug development. Orphans now constitute a significant portion of novel drugs hitting the market. It's a highly competitive segment, and we are starting to see some of the dynamics of the wider pharma market coming into play in the more competitive corners of rare diseases.
In this upcoming webinar, Melanie Senior, the author of Evaluate's new Orphan Drugs report, will join Jeremy M. Levin, CEO of Ovid Therapeutics, and Andreas Hadjivasiliou, Managing Analyst at Evaluate, to discuss the outlook for the sector over the next few years.

Topics up for discussion:

  • The potential impact of the Inflation Reduction Act on rare diseases and orphan drugs
  • The size of the orphan drug market and key areas of growth
  • Key players in the market
  • The state of the orphan drug pipeline

Your Hosts:

Jeremy M. Levin,
CEO of Ovid Therapeutics
Andreas Hadjivasiliou,
Managing Analyst at Evaluate
Melanie Senior,
Author of Evaluate's Orphan Drugs report